Is Processa Pharmaceuticals, Inc. (PCSA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.1% / 30% | 18.6% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.1% / 33% | 18.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 2.3% / 33% | 36.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.1% / 33% | 18.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 2.3% / 33% | 36.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -373.0% | |
| Return on Assets (ROA) | -158.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$11M |
| Total Debt | $73,507 |
| Current Ratio | 2.5 |
| Total Assets | $3M |
Price & Trading
| Last Close | $2.24 |
| 50-Day MA | $2.63 |
| 200-Day MA | $5.17 |
| Avg Volume | 73K |
| Beta | 1.1 |
|
52-Week Range
$1.76
| |
About Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Processa Pharmaceuticals, Inc. (PCSA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Processa Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Processa Pharmaceuticals, Inc.'s debt ratio?
Processa Pharmaceuticals, Inc.'s debt ratio is 1.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.3%.
What are Processa Pharmaceuticals, Inc.'s key financial metrics?
Processa Pharmaceuticals, Inc. has a market capitalization of $6M. Return on equity stands at -373.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.